Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Rectal Neoplasms 6Colonic Neoplasms 5Prostatic Neoplasms 4Leukemia 4Colorectal Neoplasms 4Breast Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Carcinoma, Renal Cell 3Unspecified Adult Solid Tumor, Protocol Specific 2Squamous Cell Carcinoma of Head and Neck 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Oligodendroglioma 1Neoplasms, Plasma Cell 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1

Interventions

Doxorubicin 15Exercise 9Cyclophosphamide 9Dexrazoxane 8Razoxane 6Carvedilol 6Vincristine 4Trastuzumab 4Radiotherapy 4Filgrastim 4Docetaxel 4Methotrexate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Echocardiography 3Atorvastatin 3salicylhydroxamic acid 2sacubitril and valsartan sodium hydrate drug combination 2empagliflozin 2dapagliflozin 2Tablets 2Silymarin 2Prednisone 2Paclitaxel 2Neoadjuvant Therapy 2Leucovorin 2Ivabradine 2High-Intensity Interval Training 2Epirubicin 2Electrocardiography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cardiotoxicity × Reverse Transcriptase Polymerase Chain Reaction × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡